Please provide your email address to receive an email when new articles are posted on . Dupilumab was approved for treatment of chronic spontaneous urticaria in patients aged 12 years and older.
In a retrospective review of 184 children with atopic dermatitis (AD) treated with dupilumab, four of the 19 who received live-attenuated vaccines experienced adverse events, including one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback